Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease.

MLA

George, Alex, et al. “Novel Dose Escalation to Predict Treatment with Hydroxyurea (NDEPTH): A Randomized Controlled Trial of a Dose-Prediction Equation to Determine Maximum Tolerated Dose of Hydroxyurea in Pediatric Sickle Cell Disease.” American Journal of Hematology, vol. 95, no. 9, Sept. 2020, pp. E242–44. EBSCOhost, https://doi.org/10.1002/ajh.25883.

APA

George, A., Dinu, B., Estrada, N., Minard, C. G., Hurwitz, R., Mahoney, D. H., Yates, A. M., Vaughan, M., Carmouche, A., Airewele, G., Kirk, S. E., Fasipe, T., Uwaezuoke, P., & Ware, R. E. (2020). Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease. American Journal of Hematology, 95(9), E242–E244. https://doi.org/10.1002/ajh.25883

Chicago

George, Alex, Bogdan Dinu, Norma Estrada, Charles G Minard, Richard Hurwitz, Donald H Mahoney, Amber M Yates, et al. 2020. “Novel Dose Escalation to Predict Treatment with Hydroxyurea (NDEPTH): A Randomized Controlled Trial of a Dose-Prediction Equation to Determine Maximum Tolerated Dose of Hydroxyurea in Pediatric Sickle Cell Disease.” American Journal of Hematology 95 (9): E242–44. doi:10.1002/ajh.25883.